Q-linea (QLINEA) Q4 2024 earnings summary

Executive summary

• 2024 marked a pivotal year with FDA clearance, transition to commercialization, and expansion of the commercial team, establishing Q-linea as a leader in rapid AST with the highest number of placed instruments and strong clinical evidence.

• The company targeted high-risk patient populations, especially in sepsis, and expanded its addressable market through new geographies and clinical applications, with early adopters and channel partners in Europe, the U.S., and the Middle East driving market penetration.

• Commercial activity accelerated with first next-generation rapid AST placements, first US commercial sale in January 2025, and key development projects completed.

• Cost-cutting programs reduced annual costs by SEK 60 million, with savings reinvested in commercial capacity and headcount reduced from 127 to 94.

• Rights issue and directed share issue raised approximately SEK 216 million before costs, supporting ongoing operations.

Financial highlights

• Net sales for Q4 2024 were SEK 0.2 million, with FY 2024 income at SEK 5.8 million, primarily from reagent rental contracts in Italy.

• Full year 2024 operating result was SEK -213.6 million, with cash and cash equivalents at year-end of SEK 25.7 million, down from SEK 81.9 million the previous year.

• Rights issue and directed issue raised SEK 216 million before costs, with SEK 93 million net liquidity after loan repayments; additional warrant component could raise SEK 102–108 million.

• Loans from principal owner Next2B totaled SEK 99.5 million, with SEK 50 million netted in the rights issue and SEK 9 million repaid.

• Group equity at year-end was SEK -27.5 million, while parent company equity was SEK 74.2 million.

Outlook and guidance

• 2025 is expected to see accelerated commercial progress, with increased contracted units, more geographic expansion, and higher average tests per instrument.

• Clinical progress is expected with completion of key studies, expanded test menus, and new FDA submissions.

• Guidance remains for breakeven during 2027, with a focus on gross margin improvement, cost of goods reduction, and maintaining OpEx discipline.

• Additional liquidity from the second part of the rights issue is needed to fund operations for the next 12 months; board is optimistic about securing further financing but notes uncertainty if not achieved.